Pressmeddelanden, rapporter och bolagsmeddelande för CHOSA Oncology
Press release from Companies: RhoVac plans for a fully guaranteed convertible loan rights issue, to finance activities following a successful clinical phase IIb study outcome
More from the company: RhoVac deltar i lunchseminariet: Kan det komma tillbaka? under Cancerveckan arrangerat av FOKUS patient[®]
Press release from Companies: The Canadian Intellectual Property Office intends to grant RhoVac’s patent application for RV001 (onilcamotide) cancer vaccine
Press release from Companies: Kanadensiska patentverket avser bevilja RhoVacs patentansökan för cancervaccinet (RV001) onilcamotide
Press release from Companies: RhoVac's co-founder and board member sells a fraction of his shares to cover taxes on holdings
Press release from Companies: RhoVacs medgrundare och styrelsemedlem Anders Ljungqvist säljer en del av sina aktier för att täcka dansk skatt på innehav
Press release from Companies: Another clean interim safety review of RhoVac’s clinical phase IIb study in prostate cancer
Press release from Companies: Ytterligare en stark interimsanalys av patientsäkerheten för RhoVacs kliniska fas IIb-studie i prostatacancer
Press release from Companies: RhoVac's market research shows great potential for a cancer vaccine preventing recurrence of metastatic disease in multiple cancers
Press release from Companies: RhoVacs marknadsundersökning visar på stor potential för ett fungerande cancervaccin som förebygger återfall i metastaserad sjukdom i flera olika cancerformer